ArticleJournal of biosciences2015
Anti-tumour immune effect of oral administration of Lactobacillus plantarum to CT26 tumour-bearing mice.
Article in Journal of biosciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Pooled it
- A Phase II Randomized Clinical Trial and Mechanistic Studies Using Improved Probiotics to Prevent Oral Mucositis Induced by Concurrent Radiotherapy and Chemotherapy in Nasopharyngeal Carcinoma.Frontiers in immunology · 2021Trial
- Molecular mechanisms involved in the anticancer activities of probiotics and postbiotics.Cancer cell international · 2026Review
- Translational approaches in microbiome research: from functional mechanisms to next-generation therapeutics.Frontiers in microbiology · 2026Review
- The role of gut microbiota and its metabolites in preventing oncogenesis.Frontiers in cell and developmental biology · 2026Review
- Application and Challenges of Using ProbioticDiseases (Basel, Switzerland) · 2025Review
- Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Insight into microbial extracellular vesicles as key communication materials and their clinical implications for lung cancer (Review).International journal of molecular medicine · 2025Review
- Immunoregulatory role of pulmonary microbiota in lung cancer: a bibliometric analysis.Discover oncology · 2025Article
- Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology.Microbial biotechnology · 2025Review
- Potential of natural products and gut microbiome in tumor immunotherapy.Chinese medicine · 2024Review
- The inhibitory effects of the novelHeliyon · 2024Article
- Immunomodulation aspects of gut microbiome-related interventional strategies in colorectal cancer.Medical oncology (Northwood, London, England) · 2024Review
- Article
- Lactic Acid Bacteria-Derived Postbiotics as Adjunctive Agents in Breast Cancer Treatment to Boost the Antineoplastic Effect of a Conventional Therapeutic Comprising Tamoxifen and a New Drug Candidate: An Aziridine-Hydrazide Hydrazone Derivative.Molecules (Basel, Switzerland) · 2024Article
- Microbiome bacterial influencers of host immunity and response to immunotherapy.Cell reports. Medicine · 2024Review
- A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy.International journal of molecular sciences · 2024Review
- The Impact of the Gut Microbiome, Environment, and Diet in Early-Onset Colorectal Cancer Development.Cancers · 2024Review
- Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies.iMeta · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most prevalent forms of cancer that shows a high mortality and increasing incidence. There are numerous successful treatment options for CRC, including surgery, chemotherapy, radiotherapy and immunotherapy; however, their side effects and limitations are considerable. Probiotics may be an effective strategy for preventing and inhibiting tumour growth through stimulation of host innate and adaptive immunity. We investigated and compared potential anti-tumour immune responses induced by two isolated Lactobacillus strains, Lactobacillus plantarum A and Lactobacillus rhamnosus b, by pre-inoculating mice with lactobacilli for 14 days. Subsequently, subcutaneous and orthotopic intestinal tumours were generated in the pre-inoculated mice using CT26 murine adenocarcinoma cells and were assessed for response against the tumour. Our results indicated that oral administration with L. plantarum inhibited CT26 cell growth in BALB/c mice and prolonged the survival time of tumour-bearing mice compared with mice administered L. rhamnosus. L. plantarum produced protective immunity against the challenge with CT26 cells by increasing the effector functions of CD8+ and natural killer (NK) cell infiltration into tumour tissue, up-regulation of IFN-gamma (but not IL-4 or IL-17) production, and promotion of Th1-type CD4+ T differentiation. Consequently, our results suggest that L. plantarum can enhance the anti-tumour immune response and delay tumour formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.